Novel endomorphin analogues CEMR‐1 and CEMR‐2 produce potent and long‐lasting antinociception with a favourable side effect profile at the spinal level
Authors:
- 10 January 2024
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (8) , 1268-1289
Abstract
Background and Purpose: Endomorphins have shown great promise as pharmaceutics for the treatment of pain. We have previously confirmed that novel endomorphin analogues CEMR‐1 and CEMR‐2 behaved as potent μ agonists and displayed potent antinociceptive activities at the supraspinal and peripheral levels. The present study was undertaken to evaluate the antinociceptive properties of CEMR‐1 and CEMR‐2 following intrathecal (i.t.) administration. Furthermore, their antinociceptive tolerance and opioid‐like side effects were also determined.Experimental Approach: The spinal antinociceptive effects of CEMR‐1 and CEMR‐2 were determined in a series of pain models, including acute radiant heat paw withdrawal test, spared nerve injury‐induced neuropathic pain, complete Freund's adjuvant‐induced inflammatory pain, visceral pain and formalin pain. Antinociceptive tolerance was evaluated in radiant heat paw withdrawal test.Key Results: Spinal administration of CEMR‐1 and CEMR‐2 produced potent and prolonged antinociceptive effects in acute pain. CEMR‐1 and CEMR‐2 may produce their antinociception through distinct μ receptor subtypes. These two analogues also exhibited significant analgesic activities in neuropathic, inflammatory, visceral and formalin pain at the spinal level. It is noteworthy that CEMR‐1 showed non‐tolerance‐forming analgesic properties, while CEMR‐2 exhibited substantially reduced antinociceptive tolerance. Furthermore, both analogues displayed no or reduced side effects on conditioned place preference response, physical dependence, locomotor activity and gastrointestinal transit.Conclusions and Implications: The present investigation demonstrated that CEMR‐1 and CEMR‐2 displayed potent and long‐lasting antinociception with a favourable side effect profile at the spinal level. Therefore, CEMR‐1 and CEMR‐2 might serve as promising analgesic compounds with minimal opioid‐like side effects.Keywords
Funding Information
- National Natural Science Foundation of China (31770826, 32071261)
- State Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources, Ministry of Education
- Guangxi Normal University (CMEMR2022‐B01)
- Natural Science Foundation of Heilongjiang Province (LH2020C065)
- Harbin Institute of Technology (30620210008, HIT.OCEF.2022028)
This publication has 84 references indexed in Scilit:
- The Effect of Pro2 Modifications on the Structural and Pharmacological Properties of Endomorphin-2Journal of Medicinal Chemistry, 2012
- Functional Selectivity at the μ-Opioid Receptor: Implications for Understanding Opioid Analgesia and TolerancePharmacological Reviews, 2011
- Pain as a global public health priorityBMC Public Health, 2011
- Endomorphins: potential roles and therapeutic indications in the development of opioid peptide analgesic drugsMedicinal Research Reviews, 2011
- Recent Advances in Endomorphin EngineeringChemMedChem, 2010
- Nonresolving InflammationCell, 2010
- DAMGO and 6β-glycine substituted 14-O-methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferensBrain Research Bulletin, 2007
- Assessment and analysis of mechanical allodynia-like behavior induced by spared nerve injury (SNI) in the mousePain, 2006
- Structure−Activity Study on the Phe Side Chain Arrangement of Endomorphins Using Conformationally Constrained AnaloguesJournal of Medicinal Chemistry, 2003
- μ-Opposing actions of the κ-opioid receptorTrends in Pharmacological Sciences, 1998